Background
Phase 3, multicenter, randomized, open-label trial (PhALLCON, NCT03589326). N=245 adults with newly diagnosed Ph-positive (BCR::ABL1-positive) ALL receiving a reduced-intensity chemotherapy backbone, randomized 2:1 to ponatinib vs imatinib. Chemotherapy comprised 3 cycles of vincristine + dexamethasone induction, 6 cycles of alternating methotrexate/cytarabine consolidation, then 11 cycles of vincristine/prednisone maintenance — intentionally reduced-intensity vs hyperCVAD or GRAALL backbones. Published JAMA 2024; supported FDA accelerated approval.
Interventions and follow up
Arm A: Ponatinib 30 mg PO daily + reduced-intensity chemotherapy (N=164)
Arm B: Imatinib 600 mg PO daily + reduced-intensity chemotherapy (N=81)
Primary endpoint: MRD-negative complete remission at end of induction
Median follow-up: NR (regulatory submission data)
Arm B: Imatinib 600 mg PO daily + reduced-intensity chemotherapy (N=81)
Primary endpoint: MRD-negative complete remission at end of induction
Median follow-up: NR (regulatory submission data)
Results
MRD-negative CR at end of induction (primary): 34.4% (ponatinib) vs 16.7% (imatinib); risk difference 0.18 (95% CI 0.06–0.29), P=.002
CR/CRi (overall): 94.5% vs 91.4% — comparable induction CR
EFS: Favored the ponatinib arm; OS data immature at primary analysis
Allo-HSCT in CR1: Not mandated (investigator decision); deeper molecular remission in the ponatinib arm
CR/CRi (overall): 94.5% vs 91.4% — comparable induction CR
EFS: Favored the ponatinib arm; OS data immature at primary analysis
Allo-HSCT in CR1: Not mandated (investigator decision); deeper molecular remission in the ponatinib arm
Adverse events
Cardiovascular (ponatinib vs imatinib): Arterial thrombotic events any grade ~11% vs ~3%; hypertension ~37% vs ~12%; venous thromboembolism ~5% vs ~0%
Hematologic/other: Hematologic toxicities comparable between arms; grade ≥3 hepatotoxicity ~5% with ponatinib; no excess pancreatitis at the reduced 30 mg dose; dose reduction to 15 mg allowed after MRD response
Hematologic/other: Hematologic toxicities comparable between arms; grade ≥3 hepatotoxicity ~5% with ponatinib; no excess pancreatitis at the reduced 30 mg dose; dose reduction to 15 mg allowed after MRD response
Conclusions
Ponatinib + reduced-intensity chemotherapy produced a significantly higher MRD-negative CR rate at end of induction than imatinib (34% vs 17%), establishing ponatinib as the preferred TKI partner for reduced-intensity frontline regimens in Ph+ ALL. The FDA granted accelerated approval to ponatinib + chemotherapy for frontline Ph+ ALL based on this trial.
Key Limitations
OS data immature at primary analysis — MRD-negative CR is a surrogate (though clinically validated) endpoint; final OS awaited. The 2:1 randomization complicates balanced statistical comparison. Imatinib is no longer the standard comparator for Ph+ ALL (dasatinib-based regimens are common); ponatinib vs dasatinib would be more informative. The reduced-intensity backbone limits direct comparison with chemo-free (D-ALBA) or GRAALL-type regimens. Ponatinib cardiovascular risk (arterial events ~11%) warrants careful patient selection and monitoring, particularly in older patients.
Clinical Context
PhALLCON established ponatinib + reduced-intensity chemotherapy as a frontline standard for Ph+ ALL, with FDA accelerated approval (March 2024). For chemo-free approaches, D-ALBA (dasatinib + blinatumomab) is preferred. The optimal TKI for Ph+ ALL is now a choice among ponatinib (PhALLCON) and dasatinib (D-ALBA), balancing depth of molecular response, cardiovascular risk, and chemotherapy tolerance. ESMO and ELN frameworks endorse third-generation TKI-anchored frontline therapy in Ph+ ALL.